CB Consultancy provides services in planning, construction management, and operation of industrial facilities in various sectors, including pharmaceuticals, biotechnology, chemicals, analytical and scientific service providers, and the med-tech industry. Its customers include Takeda, Novartis, Johnson & Johnson and Sinopharm.

“The cooperation between CB Consultancy and Zeta has proven its worth since 2013," commented Andreas Marchler, CEO of Lieboch, Austria-based Zeta. "Building on this strong foundation of trust and successful collaboration, CB Consultancy and Zeta have decided to further deepen their cooperation through this share acquisition,” he added.

Combining their strengths, Zeta and CB Consultancy continue their partnership and work closely together in project initiation and execution, focusing on conceptual optimization within the project lifecycle.

Zeta said the journey of newly developed compounds from the laboratory through preclinical phase and early GxP clinical production, followed by scaling up the manufacturing process to industrial scale, and finally to market in a safe routine manufacturing facility is a complex, challenging process for the pharmaceutical and biotech industries. Therefore, risk and complexity management in manufacturing biopharmaceutical products are key challenges confronting companies in this industry.